CONCERN
(D)
Potential for Harm - no one hurt, but risky conditions existed
Deficiency F0625
(Tag F0625)
Could have caused harm · This affected 1 resident
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on staff interview, facility document review, and clinical record review, it was determined that the facility staff failed...
Read full inspector narrative →
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on staff interview, facility document review, and clinical record review, it was determined that the facility staff failed to issue a bed hold notice to one of 17 residents in the survey sample, Resident #34.
The findings include:
For Resident #34 (R34), the facility failed to issue a bed hold notice when the resident was transferred to the hospital on [DATE].
A review of R34's clinical record revealed the resident was transferred and admitted to the hospital on [DATE]. The resident was readmitted to the facility on [DATE].
Further review of R34's clinical record failed to reveal evidence a bed hold notice was issued to the resident or to the RP (responsible party).
On 3/22/23 at 8:12 a.m., ASM (administrative staff member) #2, the director of health services, was interviewed. She stated a bed hold notice had not been issued to R34 on 12/13/22. She stated the resident is unable to sign for themselves, and the resident's (significant other) was unable to sign in a timely manner. She stated the facility has contracts with its residents, and there is never a question if the resident will be able to return to the facility.
On 3/22/23 at 4:30 p.m., ASM (administrative staff member) #1, the administrator, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
A review of the facility policy, Bed Hold Policy, revealed, in part: A continuing care contract .stipulates that a bed in the Health Care Center be available for a LCC (life care contract) resident if and when it is needed .Residents who do not have a life care/continuing care contract .are considered per diem and are not guaranteed a bed unless it is paid for through daily charges or a Bed Hold Agreement .[name of facility] cannot guarantee the availability of a bed at the time the resident needs or desires to return unless there is a signed Bed Hold Agreement.
No further information was provided prior to exit.
CONCERN
(D)
Potential for Harm - no one hurt, but risky conditions existed
Deficiency F0655
(Tag F0655)
Could have caused harm · This affected 1 resident
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on staff interview and clinical record review, the facility staff failed to provide residents (or their representatives) w...
Read full inspector narrative →
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on staff interview and clinical record review, the facility staff failed to provide residents (or their representatives) with a summary of the baseline care plan for two of 17 residents in the survey sample, Residents #97 and #98.
The findings include:
1. For Resident #97 (R97), the facility staff failed to provide the resident (or their representative) a summary of the baseline care plan.
R97 was admitted to the facility on [DATE]. A review of R97's clinical record (including the baseline care plan effective 3/14/23, and progress notes for March 2023) failed to reveal the facility staff provided R97 or the resident's representative a summary of the baseline care plan.
On 3/21/23 at 4:54 p.m., an interview was conducted with ASM (administrative staff member) #2, (the director of health services). ASM #2 stated that upon completion of the baseline care plan, the minimum data set coordinator is supposed to finalize the baseline care plan and provide a copy to the resident and/or family. ASM #2 stated there was no evidence this was done for (R97). At this time, ASM #1 (the administrator) and ASM #2 were made aware of the above concern. On 3/23/23 at 7:15 a.m., per ASM #2, the facility did not have a policy regarding baseline care plans.
2. For Resident #98 (R98), the facility staff failed to provide the resident (or their representative) a summary of the baseline care plan.
R98 was admitted to the facility on [DATE]. A review of R98's clinical record (including the baseline care plan effective 3/10/23, and progress notes for March 2023) failed to reveal the facility staff provided R97 or the resident's representative a summary of the baseline care plan.
On 3/21/23 at 4:54 p.m., an interview was conducted with ASM (administrative staff member) #2, (the director of health services). ASM #2 stated that upon completion of the baseline care plan, the minimum data set coordinator is supposed to finalize the baseline care plan and provide a copy to the resident and/or family. ASM #2 stated there was no evidence this was done for (R98). At this time, ASM #1 (the administrator) and ASM #2 were made aware of the above concern.
No further information was provided by the facility staff.
CONCERN
(D)
Potential for Harm - no one hurt, but risky conditions existed
Deficiency F0657
(Tag F0657)
Could have caused harm · This affected 1 resident
Based on observation, staff interview, facility document review, and clinical record review, the facility staff failed to revise a resident's care plan for one of 17 residents in the survey sample, Re...
Read full inspector narrative →
Based on observation, staff interview, facility document review, and clinical record review, the facility staff failed to revise a resident's care plan for one of 17 residents in the survey sample, Resident #34.
The findings include:
For Resident #34 (R34), the facility staff failed to update the resident's care plan with the resident's use of a knee brace and non-weightbearing status.
On 3/21/23 at 8:38 a.m., R34 was seated at a table in the dining room. A knee brace was visible on the resident's right knee.
A review of R34's clinical record revealed the following orders:
Resident to be non-weight bearing for 6 weeks or until physician releases. This order was dated 2/5/23.
R (right) knee neoprene brace to be on when out of bed &skin check to be performed on removal of brace qs (every shift). This order was written 2/23/23.
A review of R34's comprehensive care plan dated 9/8/22 revealed no information regarding the knee brace or the non-weightbearing status.
On 3/22/23 at 1:25 p.m., LPN (licensed practical nurse) #1, the MDS (minimum data set) coordinator was interviewed. She stated she is responsible for updating the care plans as new opportunities arise with changes in residents' conditions. She stated the team meets daily and weekly to review new medications, treatments, or condition changes, and that the knee brace and non-weightbearing status should be on the care plan. After reviewing R34's care plan, she stated she could not determine that the care plan had been updated.
On 3/22/23 at 4:30 p.m., ASM (administrative staff member) #1, the administrator, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
A review of the facility policy, Care Plan, Comprehensive, revealed, in part: The plan is periodically reviewed and revised by a team of qualified persons after each assessment. The resident and / or families are involved in care planning and updating to the extent possible.
No further information was provided prior to exit.
CONCERN
(D)
Potential for Harm - no one hurt, but risky conditions existed
Quality of Care
(Tag F0684)
Could have caused harm · This affected 1 resident
Based on staff interview and clinical record review, the facility staff failed to provide care and services to maintain a resident's highest level of well-being for one of 17 residents in the survey s...
Read full inspector narrative →
Based on staff interview and clinical record review, the facility staff failed to provide care and services to maintain a resident's highest level of well-being for one of 17 residents in the survey sample, Resident #35.
The findings include:
For Resident #35 (R35), the facility staff failed to obtain a physician recommended urinalysis on 2/25/23.
A review of R35's clinical record revealed a nurse's note dated 2/25/23 that documented, CNA (Certified nursing assistant) (name) reports that it appears resident has blood in (the resident's) urine. CNA showed this nurse resident's adult brief and it did have blood mixed in with the urine. This nurse placed a note in the doctor communication book asking that doctor assess resident. Further review of R35's clinical record failed to reveal any further documentation regarding bloody urine or that this was addressed by the physician.
On 3/21/23 at 11:27 a.m., ASM (administrative staff member) #2 (the director of health services) presented a provider communication log dated 2/25/23. The log documented, Based on resident's undergarment, it looks as though (the resident) has blood in (the resident's) urine (possible UTI [urinary tract infection]). The physician's response documented, UA C&S (urinalysis with culture and sensitivity). ASM #2 stated the urinalysis was never obtained.
On 3/22/23 at 10:53 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated that if there is a non-emergent medical concern and the physician is not in the building then the nurses will write the concern in a communication log. LPN #2 stated that the next time the physician comes in, she checks the book, makes her assessment, gives verbal orders or writes the orders in the book. LPN #2 stated the nurses are responsible for creating the order in the computer system and carrying out the order.
On 3/22/23 at 2:34 p.m., ASM #1 (the administrator) and ASM #2 were made aware of the above concern. A policy regarding the implementation of physician recommendations was requested. The policy provided and titled, Documentation of the Clinical Record failed to document information regarding the above concern.
CONCERN
(D)
Potential for Harm - no one hurt, but risky conditions existed
Food Safety
(Tag F0812)
Could have caused harm · This affected 1 resident
Based on observation, staff interview and facility document review, the facility staff failed to store food in a sanitary manner in one of four kitchens, the Wisteria kitchen.
The findings include:
Th...
Read full inspector narrative →
Based on observation, staff interview and facility document review, the facility staff failed to store food in a sanitary manner in one of four kitchens, the Wisteria kitchen.
The findings include:
The facility staff failed to label and date a container of prepared tuna salad observed in the Wisteria kitchen.
On 3/20/23 at 6:43 p.m., observation of the Wisteria kitchen was conducted with OSM (other staff member) #1 (the dining services manager). A metal container of prepared tuna salad was observed in the refrigerator. The container did not contain a label documenting the contents or the date. OSM #1 identified the contents as tuna salad and discarded it.
On 3/21/23 at 4:25 p.m., an interview was conducted with OSM #1. OSM #1 stated the name of food products should be labeled on the containers. OSM #1 stated this should be done in case there is a need to trace back to the product.
On 3/21/23 at 4:52 p.m., ASM (administrative staff member) #1 (the administrator) and ASM #2 (the director of health services) were made aware of the above concern.
The facility policy titled, Food Safety documented, 10. All foods prepared in operation must be covered and labeled as to the contents and date of preparation prior to storage in refrigerators and freezers. Labels for potentially hazardous foods also must include time of storage.
CONCERN
(D)
Potential for Harm - no one hurt, but risky conditions existed
Medical Records
(Tag F0842)
Could have caused harm · This affected 1 resident
Based on staff interview, facility document review and clinical record review, the facility staff failed to maintain a complete and accurate clinical record for one of 17 residents in the survey sampl...
Read full inspector narrative →
Based on staff interview, facility document review and clinical record review, the facility staff failed to maintain a complete and accurate clinical record for one of 17 residents in the survey sample, Resident #14.
The findings include:
For Resident #14 (R14), the facility staff failed to document the resident's refusal of a pressure injury assessment on 3/7/23.
A review of R14's clinical record revealed an assessment of R14's coccyx pressure injury on 2/28/23. Further review of R14's clinical record failed to reveal another assessment of the resident's coccyx pressure injury until 3/17/23.
On 3/22/23 at 10:50 a.m., an interview was conducted with LPN (licensed practical nurse) #2, who was the nurse who typically documented pressure injury assessments. LPN #2 stated she was off on 3/7/23 but her understanding was that the physician and another nurse attempted to assess R14's pressure injury on that date and the resident refused because visitors were present. LPN #2 stated there was no note to evidence this, but the nurse was going to document a late entry.
A nurse's note created on 3/21/23, and effective for 3/7/23 documented a late entry that R14 preferred to not have the pressure injury assessed during wound rounds on that date because the resident had visitors.
On 3/22/23 at 1:11 p.m., an interview was conducted with RN (registered nurse) #1. RN #1 stated a resident's refusal of a pressure injury assessment because, It's something that was wanted to be done and they are refusing for us to do what was needed.
On 3/22/23 at 2:34 p.m., ASM (administrative staff member) #1 (the administrator) and ASM #2 (the director of health services) were made aware of the above concern.
The facility policy titled, Documentation of the clinical record documented, The nurse's notes are the responsibility of the licensed nursing staff. They must show the progress the resident is making following orders written by the physician. It provides a permanent legal record of the nursing care, treatments, and medications administered.
CONCERN
(E)
Potential for Harm - no one hurt, but risky conditions existed
Comprehensive Care Plan
(Tag F0656)
Could have caused harm · This affected multiple residents
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on resident interview, staff interview, clinical record review and facility document review it was determined that the fac...
Read full inspector narrative →
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on resident interview, staff interview, clinical record review and facility document review it was determined that the facility staff failed to implement the comprehensive care plan for six of 17 residents in the survey sample, Residents #4, #36, #22, #6, #17 and #34.
The findings include:
1. For Resident #4 (R4), the facility staff failed to implement the comprehensive care plan to provide non-pharmacological interventions prior to administration of as needed Tylenol with Codeine #3 (1).
On the most recent MDS (minimum data set), a significant change assessment with an ARD (assessment reference date) of 1/4/2023, the resident scored 13 out of 15 on the BIMS (brief interview for mental status) assessment, indicating the resident was cognitively intact for making daily decisions. Section J documented R4 having pain frequently and receiving as needed pain medications. Section J further documented R4 not receiving non-medication interventions for pain.
On 3/21/2023 at 11:22 a.m., an interview was conducted with R4. R4 stated that they had pain at times and the nurses gave them medication to help. R4 stated that sometimes the staff tried to give them a pillow but most of the time they just gave the medication.
The comprehensive care plan for R4 dated 8/9/2022 documented in part, (Name of R4) has chronic pain r/t (related to) old right ankle fx (fracture) and arthritis. Date Initiated: 08/09/2022. Revision on: 01/18/2023 . Under Interventions it documented in part, .Medications as ordered. Non-medication interventions to be offered. Date Initiated: 08/25/2022. Revision on: 08/25/2022 .
The physician order's for R4 documented in part,
- Tylenol with Codeine #3 Tablet 300-30 MG (milligram) (Acetaminophen-Codeine) Give 1 tablet by mouth every 6 hours as needed for For pain scale of 6-10. Order Date: 12/22/2022. Start Date: 12/22/2022.
The eMAR (electronic medication administration record) dated 1/1/2023-1/31/2023 documented the Tylenol with Codeine #3 administered to R4 a total of 26 times for pain levels ranging from 6-10. The eMAR failed to evidence documentation of non-pharmacological interventions prior to the administration of the as needed Tylenol with Codeine #3.
The eMAR dated 2/1/2023-2/28/2023 documented the Tylenol with Codeine #3 administered to R4 a total of 14 times for pain levels ranging from 6-8. The eMAR failed to evidence documentation of non-pharmacological interventions prior to the administration of the as needed Tylenol with Codeine #3.
The eMAR dated 3/1/2023-3/31/2023 documented the Tylenol with Codeine #3 administered to R4 a total of 10 times for pain levels ranging from 7-8. The eMAR failed to evidence documentation of non-pharmacological interventions prior to the administration of the as needed Tylenol with Codeine #3.
The progress notes for R4 from 1/1/2023-3/22/2023 failed to evidence documentation of non-pharmacological interventions attempted or offered prior to the administration of the as needed pain medication documented on the eMARs.
On 3/22/2023 at 10:56 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated that the purpose of the care plan was for everyone to know what the residents problems were and for the staff to know what they were to do for the resident. LPN #2 stated that if the non-medical interventions were not documented on the eMAR that it could not be proven that they were offered or that they were implementing the care plan for the resident.
On 3/22/2023 at 11:35 a.m., ASM (administrative staff member) #2, the director of health services stated that they did not have evidence of non-pharmacological interventions offered to R4 prior to the administration of the Tylenol with Codeine #3 from 1/1/2023-3/22/2023.
The facility policy Care Plan, Comprehensive dated 10/17/2022 documented in part, .All services provided or arranged by the facility to meet the needs identified in the written plan of care meet professional standards of quality and are provided by qualified persons in accordance with each resident's written plan of care.
On 3/22/2023 at approximately 2:33 p.m., ASM #1, the administrator, ASM #2, the director of health services, ASM #3, the chief operating officer and LPN #2, the healthcare unit coordinator were made aware of the concern.
No further information was provided prior to exit.
Reference:
(1) Tylenol #3
The combination of acetaminophen and codeine is used to relieve mild to moderate pain. Acetaminophen is in a class of medications called analgesics (pain relievers) and antipyretics (fever reducers). It works by changing the way the body senses pain and by cooling the body. Codeine belongs to a class of medications called opiate (narcotic) analgesics and to a class of medications called antitussives. When codeine is used to treat pain, it works by changing the way the brain and nervous system respond to pain. When codeine is used to reduce coughing, it works by decreasing the activity in the part of the brain that causes coughing. This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a601005.html
2. For Resident #36 (R36), the facility staff failed to implement the comprehensive care plan for monitoring for adverse side effects related to the physician prescribed medication, Celexa (1).
The comprehensive care plan for R36 documented in part, (Name of R36) uses antidepressant medication Celexa r/t (related to) Depression. Date Initiated: 02/28/2022. Revision on: 02/28/2022. Under Interventions it documented in part, .Monitor/document/report PRN (as needed) adverse reactions to Antidepressant therapy: change in behavior/mood/cognition; hallucinations/delusions; social isolation, suicidal thoughts, withdrawal; decline in ADL (activities of daily living) ability, continence, no voiding; constipation, fecal impaction, diarrhea; gait changes, rigid muscles, balance probs (problems), movement problems, tremors, muscle cramps, falls; dizziness/vertigo; fatigue, insomnia; appetite loss, wt (weight) loss, n/v (nausea/vomiting), dry mouth, dry eyes. Date Initiated: 2/28/2022 . The care plan further documented, I have a mood problem r/t Major Depressive Disorder. Date Initiated: 02/10/2023. Revision on: 02/10/2023. Under Interventions it documented in part, Administer medications as ordered. Monitor/document for side effects and effectiveness. Date Initiated: 02/10/2023 .
The physician orders for R36 documented in part,
- Celexa 20mg (milligram) 1 tablet by mouth in the morning related to Major Depressive Disorder, recurrent unspecified. Order Date: 8/27/2021.
The eMARs (electronic medication administration records) dated 1/1/2023-1/31/2023, 2/1/2023-2/28/2023 and 3/1/2023-3/31/2023 for R36 documented the resident having received the Celexa as ordered daily through 3/22/2023.
On 3/22/2023 at 10:25 a.m., ASM (administrative staff member) #2, the director of health services stated that they did not have any evidence that the facility staff had been monitoring for side effects for the Celexa for R36. ASM #2 stated that monitoring should be done and they now were aware of this and it would be corrected.
On 3/22/2023 at 10:56 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated that the purpose of the care plan was for everyone to know what the residents problems were and for the staff to know what they were to do for the resident. LPN #2 stated that psychotropic medications should be monitored by staff to ensure residents did not have any side effects from them. LPN #2 stated that they should do this to make sure that the treatment they were providing was not causing any other issues to the resident. LPN #2 stated that they had not had a system in place for monitoring antidepressants, antipsychotics and antianxiety medications. LPN #2 stated that they could not say that they were implementing the care plan for the resident without evidence to support it.
On 3/22/2023 at 2:33 p.m., ASM #1, the administrator, ASM #2, the director of health services, ASM #3, the chief operating officer and LPN #2, the health care unit coordinator were made aware of the above concern.
No further information was provided prior to exit.
Reference:
(1) Celexa
Citalopram is used to treat depression. Citalopram is in a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance. This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a699001.html
3. For Resident #22 (R22), the facility staff failed to implement the comprehensive care plan for monitoring for adverse side effects related to the physician prescribed medications, Seroquel (1) and Cymbalta (2).
The comprehensive care plan for R22 documented in part, (Name of R22) uses antidepressant medication Cymbalta. Resident with dx. (diagnoses) of anxiety and adjustment disorder with depressed mood. Date Initiated: 11/04/2019. Revision on: 02/01/2023. Under Interventions it documented in part, .Monitor/document/report PRN (as needed) adverse reactions to Antidepressant therapy: change in behavior/mood/cognition; hallucinations/delusions; social isolation, suicidal thoughts, withdrawal; decline in ADL (activities of daily living) ability, continence, no voiding; constipation, fecal impaction, diarrhea; gait changes, rigid muscles, balance probs (problems), movement problems, tremors, muscle cramps, falls; dizziness/vertigo; fatigue, insomnia; appetite loss, wt (weight) loss, n/v (nausea/vomiting), dry mouth, dry eyes. Date Initiated: 11/04/2019 . The care plan also documented, [Name of R22] uses antipsychotic medication Seroquel r/t hallucinations. Date Initiated: 02/02/2023. Revision on: 02/02/2023. Under Interventions it documented in part, .Monitor/document/report PRN any adverse reactions of Psychotropic medications: unsteady gait, tardive dyskinesia, EPS (shuffling gait, rigid muscles, shaking), frequent falls, refusal to eat, difficulty swallowing, dry mouth, depression, suicidal ideations, social isolation, blurred vision, diarrhea, fatigue, insomnia, loss of appetite, weight loss, muscle cramps nausea, vomiting, behavior symptoms not usual to the person. Date Initiated: 02/02/2023 . The care plan further documented, I have a mood problem r/t Major Depressive Disorder, Anxiety Disorder and Adjustment Disorder. Date Initiated: 01/19/2023. Revision on: 01/19/2023. Under Interventions it documented in part, Administer medications as ordered. Monitor/document for side effects and effectiveness. Date Initiated: 01/19/2023 Date Initiated: 01/19/2023 .
The physician orders for R22 documented in part,
- Seroquel Tablet 25 MG (milligram) (Quetiapine Fumarate) Give 0.5 tablet by mouth in the morning for hallucinations. Order Date: 12/19/2022. Start Date: 12/20/2022.
- Seroquel Tablet 25 MG (Quetiapine Fumarate) Give 1 tablet by mouth at bedtime related to
Hallucinations, unspecified. Order Date: 11/17/2022. Start Date: 11/17/2022.
- Cymbalta Capsule Delayed Release Particles 30 MG (Duloxetine HCl) Give 1 capsule by mouth in the morning related to Major Depressive Disorder, Recurrent, Unspecified; Anxiety Disorder, Unspecified. Order Date: 12/07/2020. Start Date: 12/08/2020.
The eMARs (electronic medication administration records) dated 1/1/2023-1/31/2023, 2/1/2023-2/28/2023 and 3/1/2023-3/31/2023 for R22 documented the resident having received the Seroquel and Cymbalta as ordered daily through 3/22/2023.
On 3/22/2023 at 10:25 a.m., ASM (administrative staff member) #2, the director of health services stated that they did not have any evidence that the facility staff had been monitoring for side effects for the Seroquel and Cymbalta for R22. ASM #2 stated that monitoring should be done and they now were aware of this and it would be corrected.
On 3/22/2023 at 10:56 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated that the purpose of the care plan was for everyone to know what the residents problems were and for the staff to know what they were to do for the resident. LPN #2 stated that psychotropic medications should be monitored by staff to ensure residents did not have any side effects from them. LPN #2 stated that they should do this to make sure that the treatment they were providing was not causing any other issues to the resident. LPN #2 stated that they had not had a system in place for monitoring antidepressants, antipsychotics and antianxiety medications. LPN #2 stated that they could not say that they were implementing the care plan for the resident without evidence to support it.
On 3/22/2023 at 2:33 p.m., ASM #1, the administrator, ASM #2, the director of health services, ASM #3, the chief operating officer and LPN #2, the health care unit coordinator were made aware of the above concern.
No further information was provided prior to exit.
Reference:
(1) Seroquel
Quetiapine tablets and extended-release (long-acting) tablets are used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Quetiapine tablets and extended-release tablets are also used alone or with other medications to treat episodes of mania (frenzied, abnormally excited or irritated mood) or depression in patients with bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). In addition, quetiapine tablets and extended-release tablets are used with other medications to prevent episodes of mania or depression in patients with bipolar disorder. Quetiapine extended-release tablets are also used along with other medications to treat depression. Quetiapine tablets may be used as part of a treatment program to treat bipolar disorder and schizophrenia in children and teenagers. Quetiapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a698019.html
(2) Cymbalta
Duloxetine is used to treat depression in adults and generalized anxiety disorder (GAD; excessive worry and tension that disrupts daily life and lasts for 6 months or longer) in adults and children 7 years of age and older. Duloxetine is also used to treat pain and tingling caused by diabetic neuropathy (damage to nerves that can develop in people who have diabetes) in adults and fibromyalgia (a long-lasting condition that may cause pain, muscle stiffness and tenderness, tiredness, and difficulty falling asleep or staying asleep) in adults and children [AGE] years of age and older. It is also used to treat ongoing bone or muscle pain such as lower back pain or osteoarthritis (joint pain or stiffness that may worsen over time) in adults. Duloxetine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amounts of serotonin and norepinephrine, natural substances in the brain that help maintain mental balance and stop the movement of pain signals in the brain. This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a604030.html
5. For Resident #17 (R17), the facility staff failed to implement the comprehensive care plan for monitoring for adverse side effects related to the physician prescribed medications, Risperdal (1) and Lorazepam (2).
On the most recent MDS (minimum data set), a quarterly assessment with an ARD (assessment reference date) of 1/11/23, R17 was coded as being severely cognitively impaired for making daily decisions. The resident was coded as having received an antipsychotic medication six of seven days of the look back period, and as having received an antianxiety medication all seven days of the look back period.
A review of R17's physician orders revealed the following orders:
Risperdal Tablet 0.5 MG (risperidone) Give 1 tablet by mouth at bedtime for hallucinations and delusions. This order was dated 1/25/21.
Lorazepam Intensol Concentrate 2 MG/ML (Lorazepam) Give 0.25 ml by mouth in the morning. This order was dated 12/16/22.
Further review of R17's MARs revealed the resident received Risperdal and Lorazepam as ordered in January 2023, February 2023, and March 2023.
A review of R17's comprehensive care plan revealed, in part: Monitor the resident every shift for safety. The resident is taking ANTI-ANXIETY meds which are associated with an increased risk of confusion, amnesia, loss of balance, and cognitive impairment that looks like dementia and increases risk of falls, broken hips and legs. This portion of the care plan was initiated on 5/8/18, and updated 8/6/21. This review further revealed, in part: Monitor/document/report PRN any adverse reactions of PSYCHOTROPIC medications: unsteady gait, tardive dyskinesia, EPS (extrapyramidal side effects) (shuffling gait, rigid muscles, shaking), frequent falls, refusal to eat, difficulty swallowing, dry mouth, depression, suicidal ideations, social isolation, blurred vision, diarrhea, fatigue, insomnia, loss of appetite, weight loss, muscle cramps nausea, vomiting, behavior symptoms not usual to the person. This portion of the care plan was initiated on 1/20/22.
On 3/22/23 at 8:12 a.m., ASM #2 stated she could not provide evidence that the facility staff had been monitoring for side effects for the Lorazepam and Risperdal. ASM #2 stated the facility staff should be monitoring for side effects to make sure residents are not experiencing adverse reactions from medications that are intended to help them.
On 3/22/23 at 10:56 a.m., LPN (licensed practical nurse) #2, the unit manager, was interviewed. She stated the purpose of a care plan is for everyone to know what a resident's problems are, and how the facility staff is going to take care of those problems. She stated: It is a guide to their care. She stated if a care plan includes an intervention to monitor a resident for side effects of a medication, the nurse should be looking to make sure that the medication is not indirectly causing other problems for a resident. She stated the facility does not have a clear, concise system for documenting the monitoring of residents for medication side effects. She stated the facility staff had not been following R17's care plan.
On 3/22/23 at 4:30 p.m., ASM #1, the administrator, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
No further information was provided prior to exit.
(1) Risperidone (generic for Risperdal) is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers [AGE] years of age and older. It is also used to treat episodes of mania (frenzied, abnormally excited, or irritated mood) or mixed episodes (symptoms of mania and depression that happen together) in adults and in teenagers and children [AGE] years of age and older with bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Risperidone is also used to treat behavior problems such as aggression, self-injury, and sudden mood changes in teenagers and children 5 to [AGE] years of age who have autism (a condition that causes repetitive behavior, difficulty interacting with others, and problems with communication). Risperidone is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. This information is taken from the website https://medlineplus.gov/druginfo/meds/a694015.html.
(2) Lorazepam (brand name Ativan) is used to relieve anxiety. Lorazepam is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow for relaxation. This information is taken from the website https://medlineplus.gov/druginfo/meds/a682053.html.
6. For Resident #34 (R34), the facility staff failed to implement the comprehensive care plan for monitoring for adverse side effects related to the physician prescribed medication, Lorazepam (1).
On the most recent MDS (minimum data set), a quarterly assessment with an ARD (assessment reference date) of 12/10/22, R34 was coded as being moderately impaired for making daily decisions, having scored eight out of 15 on the BIMS (brief interview for mental status). The resident was coded as having received an antianxiety medication and an antidepressant medication on all seven days of the look back period.
A review of R34's physician orders revealed the following order: Lorazepam Oral Tablet 0.5 MG (Lorazepam) Give 1 tablet by mouth before meals for tremors. This order was dated 2/2/23.
A review of R34's March 2023 MAR (medication administration record) revealed the Lorazepam had been administered as ordered each day.
A review of R34's comprehensive care plan revealed, in part: Monitor/document/report PRN (as needed) any adverse reactions to ANTI-ANXIETY therapy: Drowsiness, lack of energy, clumsiness, slow reflexes, Slurred speech, confusion and disorientation, depression, dizziness, lightheadedness, impaired thinking and judgment, memory loss, forgetfulness, nausea, stomach upset, blurred or double vision. UNEXPECTED SIDE EFFECTS: Mania, hostility, rage, aggressive or impulsive behavior, hallucinations. This intervention was initiated 9/19/22.
On 3/22/23 at 8:12 a.m., ASM #2 stated she could not provide evidence that the facility staff had been monitoring for side effects for the Lorazepam. ASM #2 stated they facility staff should be monitoring for side effects to make sure residents are not experiencing adverse reactions from medications that are intended to help them.
On 3/22/23 at 4:30 p.m., ASM #1, the administrator, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
No further information was provided prior to exit.
(1) Lorazepam (brand name Ativan) is used to relieve anxiety. Lorazepam is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow for relaxation. This information is taken from the website https://medlineplus.gov/druginfo/meds/a682053.html.
4. For Resident #6 (R6), the facility staff failed to implement the resident's comprehensive care plan for pressure injury treatments.
A review of R6's clinical record revealed a pressure injury assessment dated [DATE] that documented the resident presented with a deep tissue injury on the outer aspect of the left lateral foot (present on admission 2/13/23). A physician's order dated 2/14/23 documented to apply skin prep to the left lateral foot wound twice a day. A review of R6's February 2023 and March 2023 MARs (medication administration records) and TARs (treatment administration records) failed to reveal the physician's order for skin prep to the left lateral foot twice a day, and failed to reveal the treatment was administered. A review of nurse's notes for February 2023 and March 2023 failed to reveal skin prep was applied to the left lateral foot on any dates except for 2/27/23, 3/1/23, 3/2/23, 3/6/23, 3/7/23 and 3/10/23.
R6's comprehensive care plan dated 2/27/23 and revised on 3/1/23 documented, (Name of R6) has actual impairment to skin integrity r/t (related to) pressure injuries .Tx (Treatment) as ordered .
On 3/22/23 at 10:40 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated nurses evidence that treatments are done by signing them off on the TAR and that would be the only physical place to see that the treatments were done.
On 3/22/23 at 10:53 a.m., another interview was conducted with LPN #2. LPN #2 stated the purpose of the care plan is, So everyone knows what the resident's problem is and what we are doing to help care for that problem and the steps for the interventions .It gives a guide to their care. In regard to care plan implementation, LPN #2 stated, The medications are on the medication MAR for the problem, the TAR has treatments, any tasks are on the poc (point of care computer system) for CNAs (certified nursing assistants).
On 3/22/23 at 2:34 p.m., ASM (administrative staff member) #1 (the administrator) and ASM #2 (the director of health services) were made aware of the above concern.
CONCERN
(E)
Potential for Harm - no one hurt, but risky conditions existed
Pressure Ulcer Prevention
(Tag F0686)
Could have caused harm · This affected multiple residents
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on staff interview, facility document review and clinical record review, the facility staff failed to provide care and ser...
Read full inspector narrative →
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on staff interview, facility document review and clinical record review, the facility staff failed to provide care and services for a pressure injury for one of 17 residents in the survey sample, Resident #6.
The findings include:
For Resident #6 (R6), the facility staff failed to evidence treatment was provided for the resident's left lateral foot pressure injury, as ordered by the physician, on multiple dates during February 2023 and March 2023.
A review of R6's clinical record revealed a pressure injury assessment dated [DATE] that documented the resident presented with a deep tissue injury on the outer aspect of the left lateral foot (present on admission 2/13/23). A physician's order dated 2/14/23 documented to apply skin prep to the left lateral foot wound twice a day. A review of R6's February 2023 and March 2023 MARs (medication administration records) and TARs (treatment administration records) failed to reveal the physician's order for skin prep to the left lateral foot twice a day and failed to reveal the treatment was completed. A review of nurse's notes for February 2023 and March 2023 failed to reveal skin prep was applied to the left lateral foot on any dates except for 2/27/23, 3/1/23, 3/2/23, 3/6/23, 3/7/23 and 3/10/23.
R6's comprehensive care plan dated 2/27/23 and revised on 3/1/23 documented, (Name of R6) has actual impairment to skin integrity r/t (related to) pressure injuries .Tx (Treatment) as ordered .
On 3/22/23 at 10:40 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated nurses evidence that treatments are done by signing them off on the TAR and that would be the only physical place to see that the treatments were done. LPN #2 stated she entered the physician order for skin prep to the left lateral foot into the computer system and when she did this, she was supposed to select an order type for TAR so the order would transfer to the TAR. LPN #2 stated she did not do this and there was no evidence that the treatment was done per physician's order.
On 3/22/23 at 2:34 p.m., ASM (administrative staff member) #1 (the administrator) and ASM #2 (the director of health services) were made aware of the above concern.
The facility policy titled, Pressure Injury Prevention and Care Protocol documented, Standard: A program of prevention, care, and treatment of pressure injury is carried out for all Health Care residents to prevent skin breakdown and promote healing.
CONCERN
(E)
Potential for Harm - no one hurt, but risky conditions existed
Deficiency F0697
(Tag F0697)
Could have caused harm · This affected multiple residents
Based on resident interview, staff interview, clinical record review and facility document review it was determined that the facility staff failed to provide a complete pain management program includi...
Read full inspector narrative →
Based on resident interview, staff interview, clinical record review and facility document review it was determined that the facility staff failed to provide a complete pain management program including implementation of non-pharmacological interventions prior to the administration of as needed pain medications for three of 17 residents in the survey sample, Residents #4, #97 and #34.
The findings include:
1. For Resident #4 (R4), the facility staff failed to evidence implementation of non-pharmacological interventions prior to administration of as needed Tylenol with Codeine #3 (1).
On the most recent MDS (minimum data set), a significant change assessment with an ARD (assessment reference date) of 1/4/2023, the resident scored 13 out of 15 on the BIMS (brief interview for mental status) assessment, indicating the resident was cognitively intact for making daily decisions. Section J documented R4 having pain frequently and receiving as needed pain medications. Section J further documented R4 not receiving non-medication interventions for pain.
On 3/21/2023 at 11:22 a.m., an interview was conducted with R4. R4 stated that they had pain at times and the nurses gave them medication to help. R4 stated that sometimes the staff tried to give them a pillow but most of the time they just gave the medication.
The physician order's for R4 documented in part,
- Tylenol with Codeine #3 Tablet 300-30 MG (milligram) (Acetaminophen-Codeine) Give 1 tablet by mouth every 6 hours as needed for For pain scale of 6-10. Order Date: 12/22/2022. Start Date: 12/22/2022.
The eMAR (electronic medication administration record) dated 1/1/2023-1/31/2023 documented the Tylenol with Codeine #3 administered to R4 a total of 26 times for pain levels ranging from 6-10. The eMAR failed to evidence documentation of non-pharmacological interventions prior to the administration of the as needed Tylenol with Codeine #3.
The eMAR dated 2/1/2023-2/28/2023 documented the Tylenol with Codeine #3 administered to R4 a total of 14 times for pain levels ranging from 6-8. The eMAR failed to evidence documentation of non-pharmacological interventions prior to the administration of the as needed Tylenol with Codeine #3.
The eMAR dated 3/1/2023-3/31/2023 documented the Tylenol with Codeine #3 administered to R4 a total of 10 times for pain levels ranging from 7-8. The eMAR failed to evidence documentation of non-pharmacological interventions prior to the administration of the as needed Tylenol with Codeine #3.
The progress notes for R4 from 1/1/2023-3/22/2023 failed to evidence documentation of non-pharmacological interventions attempted or offered prior to the administration of the as needed pain medication documented on the eMARs.
The comprehensive care plan for R4 dated 8/9/2022 documented in part, [Name of R4] has chronic pain r/t (related to) old right ankle fx (fracture) and arthritis. Date Initiated: 08/09/2022. Revision on: 01/18/2023 . Under Interventions it documented in part, .Medications as ordered. Non-medication interventions to be offered. Date Initiated: 08/25/2022. Revision on: 08/25/2022 .
On 3/22/2023 at 10:56 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated that prior to administration of as needed pain medications the nurse assessed the residents pain by asking them to describe the pain, the location of the pain and to rate the pain on a 0-10 pain scale. LPN #2 stated that they attempted non-medication interventions prior to administering medications because sometimes the pain could be alleviated without medication. LPN #2 stated that they attempted non-medication interventions such as repositioning, music or offering a snack or drink to the resident. LPN #2 stated that they would reevaluate the resident afterwards and if the pain was not relieved then would administer the medication. LPN #2 stated that the non-medication interventions were documented on the eMAR under the supplemental documentation with the as needed pain medications. LPN #2 stated that the nurses should be documenting a Y or N for yes or no when offered. LPN #2 stated that if the non-medical interventions were not documented on the eMAR that it could not be proven that they were offered to the resident prior to administration of the as needed pain medications.
On 3/22/2023 at 11:35 a.m., ASM (administrative staff member) #2, the director of health services stated that they did not have evidence of non-pharmacological interventions offered to R4 prior to the administration of the Tylenol with Codeine #3 from 1/1/2023-3/22/2023.
The facility policy Pain Management in the Long Term Care Setting dated 10/14/2022 documented in part, .Document present and past treatments utilized by the resident for the treatment of pain, include: a. medications both prescription and OTC (over the counter) and length of time on each. b. alternative treatments such as positioning, heat and cold applications. c. specify the treatment by each site of pain. d. record the effectiveness of each treatment .Considerations: .For pain related to degenerative joint disease (e.g., arthritis, etc.). Positioning, relaxation, and distraction techniques are particularly important in this population. The use of ice or heat as ordered by the physician or APRN can also be used for pain relief .
On 3/22/2023 at approximately 2:33 p.m., ASM #1, the administrator, ASM #2, the director of health services, ASM #3, the chief operating officer and LPN #2, the healthcare unit coordinator were made aware of the concern.
No further information was provided prior to exit.
Reference:
(1) Tylenol #3
The combination of acetaminophen and codeine is used to relieve mild to moderate pain. Acetaminophen is in a class of medications called analgesics (pain relievers) and antipyretics (fever reducers). It works by changing the way the body senses pain and by cooling the body. Codeine belongs to a class of medications called opiate (narcotic) analgesics and to a class of medications called antitussives. When codeine is used to treat pain, it works by changing the way the brain and nervous system respond to pain. When codeine is used to reduce coughing, it works by decreasing the activity in the part of the brain that causes coughing. This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a601005.html
3. For Resident #34 (R34), the facility staff failed to implement nonpharmacological interventions prior to administering as needed Tylenol on multiple occasions in March 2023.
On the most recent MDS (minimum data set), a quarterly assessment with an ARD (assessment reference date) of 12/10/22, R34 was coded as being moderately impaired for making daily decisions, having scored eight out of 15 on the BIMS (brief interview for mental status). The resident was coded as having experienced no pain during the look back period.
A review of R34's physician order revealed the following order: Acetaminophen Tablet (Tylenol) 325 MG (milligrams) Give 2 tablets by mouth every 4 hours as needed for pain. This order was written 2/19/23.
A review of R34's March 2023 MAR (medication administration record) revealed the resident received as needed Tylenol 15 times.
Further review of R34's clinical record revealed no evidence that nonpharmacological interventions were attempted to relieve the resident's pain prior to administration of the as needed Tylenol.
On 3/22/23 at 10:56 a.m., LPN (licensed practical nurse) #2, the unit manager, was interviewed. She stated prior to administering an as needed pain medication, she would attempt non-medical interventions such as repositioning, soft music, and offering a snack or fluids. She stated if pain can be alleviated without medication, that is in the resident's best interests. She stated attempts at nonpharmacological interventions should be documented either on the MAR or in a progress note.
On 3/22/23 at 4:30 p.m., ASM (administrative staff member) #1, the administrator, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
No further information was provided prior to exit.
2. For Resident #97 (R97), the facility staff failed to initiate a complete pain assessment and failed to attempt non-pharmacological interventions when the as needed pain medications acetaminophen and oxycodone were administered on multiple dates in March 2023.
Resident #97's (R97) baseline care plan dated 3/14/23 documented the resident takes opioids. Further review of R97's clinical record revealed a physician's order dated 3/14/23 for oxycodone 5 mg (milligrams) every four hours as needed for pain on a scale from seven to ten and a physician's order dated 3/15/23 for acetaminophen 500 mg every six hours as needed for pain on a scale from one to six. A review of R97's March 2023 MAR (medication administration record) revealed the resident was administered as needed oxycodone on 3/14/23, 3/15/23, 3/16/23, 3/18/23, 3/19/23 and 3/20/23. Further review of R97's clinical record (including the March 2023 MAR and March 2023 nurses' notes) failed to reveal a complete pain assessment (including location, quality and duration) was completed on 3/18/23, 3/19/23 and 3/20/23, and failed to reveal non-pharmacological interventions were attempted on 3/15/23, 3/16/23, 3/18/23, 3/19/23 and 3/20/23. Further review of R97's March 2023 MAR revealed the resident was administered as needed acetaminophen on 3/15/23 through 3/20/23. Further review of R97's clinical record (including the March 2023 MAR and March 2023 nurses' notes) failed to reveal a complete pain assessment (including location, quality and duration) was completed on 3/15/23, 3/16/23, 3/18/23, 3/19/23 and 3/20/23, and failed to reveal non-pharmacological interventions were attempted on 3/15/23 and 3/17/23.
On 3/22/23 at 10:53 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated non-medication interventions such as repositioning, music, food and drink should be offered prior to the administration of as needed pain medications. LPN #2 stated, Well, if you can alleviate without medication that's wonderful and sometimes you could just be uncomfortable in your sitting. If you sit too long, you may get a cramp and can alleviate with getting up and not taking a medication. In regards to pain assessments prior to the administration of as needed pain medications, LPN #2 stated, If a resident says they are having pain, of course I'm going to ask them where the pain is, how does it feel, any other specifics, radiation, pain scale on a scale of zero to ten then from there I would try a non-medication intervention and if that didn't work then I would give the prn (as needed) pain medication.
On 3/22/23 at 2:34 p.m., ASM (administrative staff member) #1 (the administrator) and ASM #2 (the director of health services) were made aware of the above concern.
CONCERN
(E)
Potential for Harm - no one hurt, but risky conditions existed
Deficiency F0757
(Tag F0757)
Could have caused harm · This affected multiple residents
Based on staff interview, facility document review and clinical record review, the facility staff failed to ensure residents were free from unnecessary medications for two of 17 residents in the surve...
Read full inspector narrative →
Based on staff interview, facility document review and clinical record review, the facility staff failed to ensure residents were free from unnecessary medications for two of 17 residents in the survey sample, Residents #97 and #98.
1. For Resident #97 (R97), the facility staff administered the as needed pain medication, oxycodone, outside of the physician ordered parameters, which was for pain rated between seven to ten (7 to 10 on a pain scale of 1-10) on 3/20/23. The staff administered oxycodone for a pain rating of three (3 out of 10 on the pain scale).
A review of R97's clinical record revealed a physician's order dated 3/14/23 for oxycodone 5 mg (milligrams) every four hours as needed for pain on a scale from seven to ten and a physician's order dated 3/15/23 for acetaminophen 500 mg every six hours as needed for pain on a scale from one to six. A review of R97's March 2023 MAR (medication administration record) revealed the resident was administered as needed oxycodone on 3/20/23 for pain rated as three.
On 3/22/23 at 10:53 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated as needed pain medications should be given per the physician ordered parameters. LPN #2 was shown R97's physician's orders for oxycodone and acetaminophen. LPN #2 stated that if R97 complained of pain rated as three then the resident should be administered Tylenol (acetaminophen). LPN #3 stated oxycodone should not be administered for pain rated as three because the oxycodone parameter is pain rated seven to ten.
On 3/22/23 at 2:34 p.m., ASM (administrative staff member) #1 (the administrator) and ASM #2 (the director of health services) were made aware of the above concern.
The facility policy titled, Pain Management in the Long Term Care Setting documented, When treating pain, start with a drug appropriate to the resident's current level of pain .
2. For Resident #98 (R98), the facility staff failed to monitor the resident for side effects (bleeding) of the anticoagulant (blood thinning) medication Eliquis (1).
A review of R98's clinical record revealed a physician's order dated 3/9/23 for Eliquis 2.5 mg (milligrams) every 12 hours for atrial fibrillation. A review of R98's March 2023 MAR (medication administration record) revealed the resident was administered Eliquis every 12 hours from 3/9/23 through 3/20/23. Further review of R98's clinical record (including the March 2023 MAR and March 2023 nurses' notes) failed to reveal the resident was monitored for side effects (bleeding) from the Eliquis.
On 3/22/23 at 1:11 p.m., an interview was conducted with RN (registered nurse) #1. RN #1 stated that if a resident takes an anticoagulant medication then the nurses certainly watch for blood in their stools, blood in their urine, petechiae (small red or purple spots on the skin caused by bleeding), and increased bruising.
On 3/22/23 at 3:53 p.m., ASM (administrative staff member) #2 (the director of health services) stated she could not provide documentation to evidence the facility staff were monitoring R98 for side effects related to anticoagulant use. ASM #2 was made aware of this concern. On 3/22/23 at 5:04 p.m., ASM #1 (the administrator) was made aware of the above concern.
The facility policy titled, Anticoagulant Therapy documented,
1. Observe for signs of bleeding
· Blood in urine or stool (black, tarry stools)
· Bleeding of gums, nose
· Small purplish, hemorrhagic spots on skin
· Excessive and easy bruising
· Bleeding from tumors, ulcers, or lesions
·Confusion, change in mental status.
Reference:
(1) ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) .Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding. This information was obtained from the website: https://www.eliquis.com/eliquis/hcp/wellcareform?cid=sem_2167331&ovl=isi&gclid=64c052d127001aa9ec1836cd1510884c&gclsrc=3p.ds&
CONCERN
(E)
Potential for Harm - no one hurt, but risky conditions existed
Medication Errors
(Tag F0758)
Could have caused harm · This affected multiple residents
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** 4. For Resident #22 (R22), the facility staff failed to monitor the resident for adverse side effects from the medications Seroq...
Read full inspector narrative →
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** 4. For Resident #22 (R22), the facility staff failed to monitor the resident for adverse side effects from the medications Seroquel (1) and Cymbalta (2).
The physician orders for R22 documented in part,
- Seroquel Tablet 25 MG (milligram) (Quetiapine Fumarate) Give 0.5 tablet by mouth in the morning for hallucinations. Order Date: 12/19/2022. Start Date: 12/20/2022.
- Seroquel Tablet 25 MG (Quetiapine Fumarate) Give 1 tablet by mouth at bedtime related to
Hallucinations, unspecified. Order Date: 11/17/2022. Start Date: 11/17/2022.
- Cymbalta Capsule Delayed Release Particles 30 MG (Duloxetine HCl) Give 1 capsule by mouth in the morning related to Major Depressive Disorder, Recurrent, Unspecified; Anxiety Disorder, Unspecified. Order Date: 12/07/2020. Start Date: 12/08/2020.
The eMARs (electronic medication administration records) dated 1/1/2023-1/31/2023, 2/1/2023-2/28/2023 and 3/1/2023-3/31/2023 for R22 documented the resident having received the Seroquel and Cymbalta as ordered daily through 3/22/2023.
The comprehensive care plan for R22 documented in part, [Name of R22] uses antidepressant medication Cymbalta. Resident with dx. (diagnoses) of anxiety and adjustment disorder with depressed mood. Date Initiated: 11/04/2019. Revision on: 02/01/2023. Under Interventions it documented in part, .Monitor/document/report PRN (as needed) adverse reactions to Antidepressant therapy: change in behavior/mood/cognition; hallucinations/delusions; social isolation, suicidal thoughts, withdrawal; decline in ADL (activities of daily living) ability, continence, no voiding; constipation, fecal impaction, diarrhea; gait changes, rigid muscles, balance probs (problems), movement problems, tremors, muscle cramps, falls; dizziness/vertigo; fatigue, insomnia; appetite loss, wt (weight) loss, n/v (nausea/vomiting), dry mouth, dry eyes. Date Initiated: 11/04/2019 . The care plan also documented, [Name of R22] uses antipsychotic medication Seroquel r/t hallucinations. Date Initiated: 02/02/2023. Revision on: 02/02/2023. Under Interventions it documented in part, .Monitor/document/report PRN any adverse reactions of Psychotropic medications: unsteady gait, tardive dyskinesia, EPS (shuffling gait, rigid muscles, shaking), frequent falls, refusal to eat, difficulty swallowing, dry mouth, depression, suicidal ideations, social isolation, blurred vision, diarrhea, fatigue, insomnia, loss of appetite, weight loss, muscle cramps nausea, vomiting, behavior symptoms not usual to the person. Date Initiated: 02/02/2023 . The care plan further documented, I have a mood problem r/t Major Depressive Disorder, Anxiety Disorder and Adjustment Disorder. Date Initiated: 01/19/2023. Revision on: 01/19/2023. Under Interventions it documented in part, Administer medications as ordered. Monitor/document for side effects and effectiveness. Date Initiated: 01/19/2023 Date Initiated: 01/19/2023 .
On 3/22/2023 at 10:25 a.m., ASM (administrative staff member) #2, the director of health services stated that they did not have any evidence that the facility staff had been monitoring for side effects for the Seroquel and Cymbalta for R22. ASM #2 stated that monitoring should be done and they now were aware of this and it would be corrected.
On 3/22/2023 at 10:56 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated that psychotropic medications should be monitored by staff to ensure residents did not have any side effects from them. LPN #2 stated that they should do this to make sure that the treatment they were providing was not causing any other issues to the resident. LPN #2 stated that they had not had a system in place for monitoring antidepressants, antipsychotics and antianxiety medications.
On 3/22/2023 at 2:33 p.m., ASM #1, the administrator, ASM #2, the director of health services, ASM #3, the chief operating officer and LPN #2, the health care unit coordinator were made aware of the above concern.
No further information was provided prior to exit.
Reference:
(1) Seroquel
Quetiapine tablets and extended-release (long-acting) tablets are used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Quetiapine tablets and extended-release tablets are also used alone or with other medications to treat episodes of mania (frenzied, abnormally excited or irritated mood) or depression in patients with bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). In addition, quetiapine tablets and extended-release tablets are used with other medications to prevent episodes of mania or depression in patients with bipolar disorder. Quetiapine extended-release tablets are also used along with other medications to treat depression. Quetiapine tablets may be used as part of a treatment program to treat bipolar disorder and schizophrenia in children and teenagers. Quetiapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a698019.html
(2) Cymbalta
Duloxetine is used to treat depression in adults and generalized anxiety disorder (GAD; excessive worry and tension that disrupts daily life and lasts for 6 months or longer) in adults and children 7 years of age and older. Duloxetine is also used to treat pain and tingling caused by diabetic neuropathy (damage to nerves that can develop in people who have diabetes) in adults and fibromyalgia (a long-lasting condition that may cause pain, muscle stiffness and tenderness, tiredness, and difficulty falling asleep or staying asleep) in adults and children [AGE] years of age and older. It is also used to treat ongoing bone or muscle pain such as lower back pain or osteoarthritis (joint pain or stiffness that may worsen over time) in adults. Duloxetine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amounts of serotonin and norepinephrine, natural substances in the brain that help maintain mental balance and stop the movement of pain signals in the brain. This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a604030.html
5. For Resident #36 (R36), the facility staff failed to evidence the resident was monitored for adverse side effects related to prescribed Celexa (1), and failed to conduct a review for a GDR (gradual dose reduction) or document that a GDR was contraindicated.
The physician orders for R36 documented in part,
- Celexa 20mg (milligram) 1 tablet by mouth in the morning related to Major Depressive Disorder, recurrent unspecified. Order Date: 8/27/2021.
The eMARs (electronic medication administration records) dated 1/1/2023-1/31/2023, 2/1/2023-2/28/2023 and 3/1/2023-3/31/2023 for R36 documented the resident having received the Celexa as ordered daily through 3/22/2023.
The comprehensive care plan for R36 documented in part, [Name of R22] uses antidepressant medication Celexa r/t (related to) Depression. Date Initiated: 02/28/2022. Revision on: 02/28/2022. Under Interventions it documented in part, .Monitor/document/report PRN (as needed) adverse reactions to Antidepressant therapy: change in behavior/mood/cognition; hallucinations/delusions; social isolation, suicidal thoughts, withdrawal; decline in ADL (activities of daily living) ability, continence, no voiding; constipation, fecal impaction, diarrhea; gait changes, rigid muscles, balance probs (problems), movement problems, tremors, muscle cramps, falls; dizziness/vertigo; fatigue, insomnia; appetite loss, wt (weight) loss, n/v (nausea/vomiting), dry mouth, dry eyes. Date Initiated: 2/28/2022 . The care plan further documented, I have a mood problem r/t Major Depressive Disorder. Date Initiated: 02/10/2023. Revision on: 02/10/2023. Under Interventions it documented in part, Administer medications as ordered. Monitor/document for side effects and effectiveness. Date Initiated: 02/10/2023 .
On 3/22/2023 at 10:25 a.m., ASM (administrative staff member) #2, the director of health services stated that they did not have any evidence that the facility staff had been monitoring for side effects for the Celexa for R36. ASM #2 stated that they did not have evidence of a review for a GDR of the Celexa for R36. ASM #2 stated that monitoring should be done and they now were aware of this and it would be corrected.
On 3/22/2023 at 10:56 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated that psychotropic medications should be monitored by staff to ensure residents did not have any side effects from them. LPN #2 stated that they should do this to make sure that the treatment they were providing was not causing any other issues to the resident. LPN #2 stated that they had not had a system in place for monitoring antidepressants, antipsychotics and antianxiety medications.
On 3/22/2023 at 2:33 p.m., ASM #1, the administrator, ASM #2, the director of health services, ASM #3, the chief operating officer and LPN #2, the health care unit coordinator were made aware of the above concern.
On 3/22/2023 at approximately 4:15 p.m., ASM #2 stated that they had confirmed with the consultant pharmacist that they did not have evidence of a review for a potential GDR for the Celexa for R36.
No further information was provided prior to exit.
Reference:
(1) Celexa
Citalopram is used to treat depression. Citalopram is in a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance. This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a699001.html
Based on staff interview, facility document review, and clinical record review, it was determined that the facility staff failed to ensure residents were free of unnecessary psychoactive medications for five of 17 residents in the survey sample, Residents #17, #34, #98, #22, and #36.
The findings include:
1.a. For Resident #17 (R17), the facility staff failed to document the rationale for extending the administration of an as needed Lorazepam beyond the original 14 days.
On the most recent MDS (minimum data set), a quarterly assessment with an ARD (assessment reference date) of 1/11/23, R17 was coded as being severely cognitively impaired for making daily decisions. The resident was coded as having received an antipsychotic medication six of seven days of the look back period, and as having received an antianxiety medication all seven days of the look back period.
A review of R17's physician orders revealed the following order: Lorazepam Concentrate 2 MG/ML (milligrams per milliliter) Give 0.25 ml by mouth every 6 hours as needed for agitation or anxiety. This order was dated 9/20/22, and was discontinued 3/17/23,
A review of R17's MARs (medication administration records) revealed the resident received as needed Lorazepam three times in January 2023, two times in February 2023, and once in March 2023.
Further review of R17's clinical record revealed no evidence that R17's order for as needed Lorazepam was reviewed or renewed beyond the initial 14 days of the order.
On 3/22/23 at 10:29 a.m., ASM (administrative staff member) #2, the director of nursing, stated she could not provide evidence that the order for as needed Lorazepam for R17 had been reviewed or discontinued beyond the initial 14 days. She stated ordinarily she gets a notification from the pharmacy for all new psychoactive medication orders for all residents. She follows up to make sure any as needed psychoactive medication orders have a 14 day stop date.
On 3/22/23 at 12:02 p.m., ASM #4, the medical director, was interviewed. She stated she is aware that Lorazepam is limited to 14 days of use as an as need medication. She stated: I know it can be renewed or lengthened. She stated: Someone should have told me in a week or two to review the medication and to see how [R17] was doing on it. She added: You shouldn't stay on a PRN (as needed medication). It should either be discontinued or scheduled.
On 3/22/23 at 4:30 p.m., ASM #1, the administrator, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
A review of the facility policy, Restraints, Chemical and Antipsychotropics, revealed, in part: A PRN (as necessary) antipsychotic agent should be used: to titrate the resident's total daily dose UP, to achieve symptoms relief; or DOWN, to avoid side effects; or DOWN, to effect a gradual dose reduction; or to manage unexpected harmful behaviors that may affect the residents or staff's safety that cannot be controlled otherwise. If such behaviors remain unmanageable after seven days, reassessment of the resident is indicated.
No further information was provided prior to exit.
(1) Lorazepam (brand name Ativan) is used to relieve anxiety. Lorazepam is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow for relaxation. This information is taken from the website https://medlineplus.gov/druginfo/meds/a682053.html.
1.b. For R17, the facility staff failed to monitor the resident for adverse side effects of Risperdal (2) and Lorazepam.
A review of R17's physician orders revealed the following orders:
Risperdal Tablet 0.5 MG (risperidone) Give 1 tablet by mouth at bedtime for hallucinations and delusions. This order was dated 1/25/21.
Lorazepam Intensol Concentrate 2 MG/ML (Lorazepam) Give 0.25 ml by mouth in the morning. This order was dated 12/16/22.
Further review of R17's MARs revealed the resident received Risperdal and Lorazepam as ordered in January 2023, February 2023, and March 2023.
A review of R17's comprehensive care plan revealed, in part: Monitor the resident every shift for safety. The resident is taking ANTI-ANXIETY meds which are associated with an increased risk of confusion, amnesia, loss of balance, and cognitive impairment that looks like dementia and increases risk of falls, broken hips and legs. This portion of the care plan was initiated on 5/8/18, and updated 8/6/21. This review further revealed, in part: Monitor/document/report PRN any adverse reactions of PSYCHOTROPIC medications: unsteady gait, tardive dyskinesia, EPS (extrapyramidal side effects) (shuffling gait, rigid muscles, shaking), frequent falls, refusal to eat, difficulty swallowing, dry mouth, depression, suicidal ideations, social isolation, blurred vision, diarrhea, fatigue, insomnia, loss of appetite, weight loss, muscle cramps nausea, vomiting, behavior symptoms not usual to the person. This portion of the care plan was initiated on 1/20/22.
On 3/22/23 at 8:12 a.m., ASM #2 stated she could not provide evidence that the facility staff had been monitoring for side effects for the Lorazepam and Risperdal. She stated they facility staff should be monitoring for side effects to make sure residents are not experiencing adverse reactions from medications that are intended to help them.
On 3/22/23 at 1:13 p.m., RN (registered nurse) #1 was interviewed. She stated when a resident first goes on a psychoactive medication, the nurses watch the resident carefully to see how the resident is responding. She stated there is no protocol or routine for this kind of monitoring.
On 3/22/23 at 4:30 p.m., ASM #1, the administrator, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
A review of the facility policy, Restraints, Chemical and Antipsychotropics, revealed, in part: Specific behaviors, nursing interventions with outcomes, and medication side effects will be monitored each shift and documented on the electronic medical record.
No further information was provided prior to exit.
(2) Risperidone (generic for Risperdal) is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers [AGE] years of age and older. It is also used to treat episodes of mania (frenzied, abnormally excited, or irritated mood) or mixed episodes (symptoms of mania and depression that happen together) in adults and in teenagers and children [AGE] years of age and older with bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Risperidone is also used to treat behavior problems such as aggression, self-injury, and sudden mood changes in teenagers and children 5 to [AGE] years of age who have autism (a condition that causes repetitive behavior, difficulty interacting with others, and problems with communication). Risperidone is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. This information is taken from the website https://medlineplus.gov/druginfo/meds/a694015.html.
2. For Resident #34 (R34), the facility staff failed to monitor the resident for adverse side effects of Lorazepam (1) and Celexa (2).
On the most recent MDS (minimum data set), a quarterly assessment with an ARD (assessment reference date) of 12/10/22, R34 was coded as being moderately impaired for making daily decisions, having scored eight out of 15 on the BIMS (brief interview for mental status). The resident was coded as having received an antianxiety medication and an antidepressant medication on all seven days of the look back period.
A review of R34's physician orders revealed the following:
Celexa Tablet 10 MG (milligram) (Citalopram Hydrobromide)
Give 1 tablet by mouth in the morning for anxiety. This order was dated 9/2/22.
Lorazepam Oral Tablet 0.5 MG (Lorazepam) Give 1 tablet by mouth before meals for tremors. This order was dated 2/2/23.
A review of R34's March 2023 MAR (medication administration record) revealed the Celexa and Lorazepam had been administered as ordered each day.
A review of R34's comprehensive care plan revealed, in part: Monitor/document/report PRN (as needed) any adverse reactions to ANTI-ANXIETY therapy: Drowsiness, lack of energy, clumsiness, slow reflexes, Slurred speech, confusion and disorientation, depression, dizziness, lightheadedness, impaired thinking and judgment, memory loss, forgetfulness, nausea, stomach upset, blurred or double vision. UNEXPECTED SIDE EFFECTS: Mania, hostility, rage, aggressive or impulsive behavior, hallucinations. This intervention was initiated 9/19/22.
On 3/22/23 at 8:12 a.m., ASM (administrative staff member) #2, the director of health services, stated she could not provide evidence that the staff had been monitoring R34 for side effects of the Celexa and Lorazepam. She stated the facility staff wants to make certain the resident is not having any adverse reactions to a medication that would require a change in the dosage or the type of medication. She stated it is the facility's responsibility to monitor consistently for signs and symptoms that a resident is reacting adversely to a medication.
On 3/22/23 at 1:13 p.m., RN (registered nurse) #1 was interviewed. She stated when a resident first goes on a psychoactive medication, the nurses watch the resident carefully to see how the resident is responding. She stated there is no protocol or routine for this kind of monitoring.
On 3/22/23 at 4:30 p.m., ASM #1, the administrator, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
No further information was provided prior to exit.
(1) Lorazepam (brand name Ativan) is used to relieve anxiety. Lorazepam is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow for relaxation. This information is taken from the website https://medlineplus.gov/druginfo/meds/a682053.html.
(2) Citalopram is used to treat depression. Citalopram is in a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance. This information is taken from the website https://medlineplus.gov/druginfo/meds/a699001.html.
3. For Resident #98 (R98), the facility staff failed to monitor the resident for adverse side effects from the antidepressant medication duloxetine (1).
A review of R98's clinical record revealed a physician's order dated 3/15/23 for duloxetine 30 mg (milligrams) in the morning for depression. A review of R98's March 2023 MAR (medication administration record) revealed the resident was administered duloxetine 30 mg every morning from 3/16/23 through 3/20/23. Further review of R98's clinical record failed to reveal the resident was monitored for side effects from duloxetine.
On 3/22/23 at 10:53 a.m., an interview was conducted with LPN (licensed practical nurse) #2. LPN #2 stated that when a resident receives an antidepressant medication, nurses should look to ensure the medication isn't causing any harm or issues.
On 3/22/23 at 3:53 p.m., ASM (administrative staff member) #2 (the director of health services) stated she could not provide documentation to evidence the facility staff were monitoring R98 for side effects related to antidepressant use. ASM #2 was made aware of this concern. On 3/22/23 at 5:04 p.m., ASM #1 (the administrator) was made aware of the above concern.
Reference:
(1) Duloxetine is used to treat depression in adults. Some side effects can be serious: unusual bruising or bleeding,
pain in the upper right part of the stomach, swelling of the abdomen, itching, yellowing of the skin or eyes, dark colored urine, loss of appetite, extreme tiredness or weakness, confusion, unsteady walking that may cause falling,
flu-like symptoms, agitation, fever, sweating, confusion, fast or irregular heartbeat, and severe muscle stiffness or twitching, loss of coordination, nausea, vomiting, or diarrhea, seizures, hallucinations (seeing things or hearing voices that do not exist), blisters or peeling skin, rash, hives, difficulty breathing or swallowing, swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs, hoarseness, difficulty urinating . This information was obtained from the website: https://medlineplus.gov/druginfo/meds/a604030.html
CONCERN
(F)
Potential for Harm - no one hurt, but risky conditions existed
Deficiency F0882
(Tag F0882)
Could have caused harm · This affected most or all residents
Based on staff interview and facility document review, it was determined that the failed to designate a qualified individual(s) onsite, who was responsible for implementing programs and activities to ...
Read full inspector narrative →
Based on staff interview and facility document review, it was determined that the failed to designate a qualified individual(s) onsite, who was responsible for implementing programs and activities to prevent and control infections.
The findings include:
The facility staff failed to ensure the acting infection preventionist had completed specialized training in infection prevention and control.
On 3/20/23 during the entrance conference, ASM (administrative staff member) #1, the administrator, was asked to provide evidence of the infection preventionist's credentials. ASM #1 stated the facility did not currently employ an infection preventionist and stated the former infection preventionist recently left the position without working out a full notice, and the facility had not yet employed a new person to fill the role. She stated no other staff members had credentials that meet the regulatory requirements of an infection preventionist. She stated she and ASM #2, the director of health services, were currently filling the role.
On 3/22/23 at 4:30 p.m., ASM #1, ASM #2, and ASM #3, the chief operating officer, were informed of these concerns.
A review of the job description for Infection Preventionist Educator revealed, in part: The infection control preventionist (IP) is responsible for identifying, investigating, monitoring, and reporting healthcare associated infections to various committees. The IP collaborates interdepartmentally to create infection prevention strategies, feedback, and sustain infection prevention strategies .Certification in infection control preferred .Knowledge of infection control practices in the healthcare setting preferred.
No further information was provided prior to exit.